Randomized Clinical Trial: Expectant Management vs Laser Treatment of Monochorionic Twins With Severe Selective Intrauterine Growth Retardation and Absent or Reverse Diastolic Flow in the Umbilical Artery

Intrauterine Growth Retardation Clinical Trial

Official title:
Randomized Clinical Trial: Expectant Management vs. Laser Treatment of Monochorionic Twins With Severe Selective Intrauterine Growth Retardation And Absent or Reverse Diastolic Flow in the Umbilical Artery

Status Completed

Clinical Trial Summary

Intrauterine growth retardation (IUGR) occurs in approximately 3 to 10% of singleton pregnancies, in 9.1% of all twins and 9.9% of monochorionic twins. IUGR in monochorionic twins typically affects only one of the fetuses (selective IUGR or SIUGR). Spontaneous demise of the SIUGR twin can occur, and may result in concomitant demise (up to 40% risk) or severe neurologic handicap (up to 30% risk) of the other twin. These complications result from exsanguination of the appropriately grown (AGA) twin into the demised SIUGR twin through placental vascular communications.

Because the adverse effects to the AGA twin of the spontaneous demise of the SIUGR twin are mediated through placental vascular anastomoses, we have proposed obliterating such anastomoses via endoscopic fetal surgery. We have developed a technique that allows us to identify the vascular anastomoses present in monochorionic placentas. Briefly, deep AV communications are identified on the surface of the placenta by noting that the terminal end of the artery of one of the fetuses does not have a corresponding returning vein to the same fetus. We have speculated that the separation of the circulations may be of benefit in monochorionic twins affected by SIUGR by preventing the adverse effects that may result from the spontaneous demise of the IUGR twin. Our goal is to evaluate with a randomized clinical trial the outcome of SIUGR managed either expectantly or with SLPCV.

Study procedures will begin with confirmation of the diagnosis and screening criteria at the Qualified Clinical Center. The patient will sign the appropriate consents and then be randomized to her treatment group. Enrollment data will be submitted to the research coordinator in Coordinating Center in Tampa. Expectant management patients will be treated by the referring physicians. Laser patients will be treated at Coordinating Center in Tampa General Hospital or qualified laser center. They may return to the referring center for follow-up. After delivery, outcome data will be sent to the research coordinator in Coordinating Center in Tampa.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01177553
Study type	Interventional
Source	University of South Florida
Contact
Status	Completed
Phase	N/A
Start date	May 2007
Completion date	February 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01665378` - Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes	N/A
Completed	`NCT00914108` - Severe Intrauterine Growth Retardation: Developmental Newborn Intensive Care Unit (NICU) Care	N/A
Active, not recruiting	`NCT01995968` - Antenatal Detection of Fetal Growth Restriction and Stillbirths Rate.	N/A
Completed	`NCT00763672` - MorbiMortality Amelioration in Preeclamptic Primiparas Study. MoMA Pre Prim Study	N/A
Withdrawn	`NCT04557475` - Transplacental Aspirin Therapy for Early Onset Fetal Growth Restriction	Phase 3
Not yet recruiting	`NCT05936333` - Exploration of Allograft Humoral Rejection in Chronic Histiocytic Intervillositis	N/A
Completed	`NCT01606774` - A Modernized Approach to Prenatal Care in Low Risk Women	N/A
Completed	`NCT01073605` - Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation	Phase 3
Recruiting	`NCT00005105` - Genetic Study of Insulin-Like Growth Factor-I Receptor Mutations in Patients With Intrauterine Growth Retardation	N/A
Completed	`NCT02229526` - Fish Oil Trials in Pregnancy for the Prevention of Pregnancy Complications ('FOTIP')	N/A
Completed	`NCT05513495` - The Effect of Neonatal Feeding Modalities on Splanchnic Oxygenation	N/A
Completed	`NCT00909974` - Effect of Prenatal Nutritional Supplementation on Birth Outcome in Hounde District, Burkina Faso	Phase 4
Completed	`NCT02691559` - The Possible Effect Of Amniotic Fluid pH On Neonatal Morbidities In Maternal Inflammation/Infection Associated Pregnancies	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.